KR20100087825A - Hangover curing agent containing taurine and flavonoid - Google Patents
Hangover curing agent containing taurine and flavonoid Download PDFInfo
- Publication number
- KR20100087825A KR20100087825A KR1020090006833A KR20090006833A KR20100087825A KR 20100087825 A KR20100087825 A KR 20100087825A KR 1020090006833 A KR1020090006833 A KR 1020090006833A KR 20090006833 A KR20090006833 A KR 20090006833A KR 20100087825 A KR20100087825 A KR 20100087825A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- weight
- taurine
- hangover
- flavonoids
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 41
- 150000002215 flavonoids Chemical class 0.000 title claims abstract description 41
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 41
- 229960003080 taurine Drugs 0.000 title claims abstract description 41
- 206010019133 Hangover Diseases 0.000 title claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims abstract description 6
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 4
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims abstract description 4
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 4
- 206010008635 Cholestasis Diseases 0.000 claims abstract 2
- 230000007870 cholestasis Effects 0.000 claims abstract 2
- 231100000359 cholestasis Toxicity 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 46
- 235000002789 Panax ginseng Nutrition 0.000 claims description 12
- 210000004207 dermis Anatomy 0.000 claims description 12
- 244000223014 Syzygium aromaticum Species 0.000 claims description 11
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 9
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 9
- 235000017803 cinnamon Nutrition 0.000 claims description 9
- 244000080767 Areca catechu Species 0.000 claims description 8
- 235000006226 Areca catechu Nutrition 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 235000020230 cinnamon extract Nutrition 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 240000008154 Piper betle Species 0.000 claims description 2
- 235000008180 Piper betle Nutrition 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims 1
- 235000021108 sauerkraut Nutrition 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 abstract description 4
- 231100000234 hepatic damage Toxicity 0.000 abstract description 3
- 230000008818 liver damage Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- -1 Agastachis Herba Substances 0.000 abstract description 2
- 244000141218 Alpinia officinarum Species 0.000 abstract 1
- 241000208340 Araliaceae Species 0.000 abstract 1
- 241000628997 Flos Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 239000001774 alpinia officinarum Substances 0.000 abstract 1
- 239000008989 cinnamomi cortex Substances 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000012360 testing method Methods 0.000 description 22
- 239000003642 reactive oxygen metabolite Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 230000003908 liver function Effects 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 8
- 210000003494 hepatocyte Anatomy 0.000 description 8
- 230000001476 alcoholic effect Effects 0.000 description 6
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- 230000034994 death Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 230000004792 oxidative damage Effects 0.000 description 4
- 238000001784 detoxification Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 206010001623 Alcoholic hangover Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02G—INSTALLATION OF ELECTRIC CABLES OR LINES, OR OF COMBINED OPTICAL AND ELECTRIC CABLES OR LINES
- H02G7/00—Overhead installations of electric lines or cables
- H02G7/16—Devices for removing snow or ice from lines or cables
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B5/00—Joining sheets or plates, e.g. panels, to one another or to strips or bars parallel to them
- F16B5/02—Joining sheets or plates, e.g. panels, to one another or to strips or bars parallel to them by means of fastening members using screw-thread
- F16B5/0266—Joining sheets or plates, e.g. panels, to one another or to strips or bars parallel to them by means of fastening members using screw-thread using springs
-
- H—ELECTRICITY
- H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
- H02G—INSTALLATION OF ELECTRIC CABLES OR LINES, OR OF COMBINED OPTICAL AND ELECTRIC CABLES OR LINES
- H02G1/00—Methods or apparatus specially adapted for installing, maintaining, repairing or dismantling electric cables or lines
- H02G1/02—Methods or apparatus specially adapted for installing, maintaining, repairing or dismantling electric cables or lines for overhead lines or cables
- H02G1/04—Methods or apparatus specially adapted for installing, maintaining, repairing or dismantling electric cables or lines for overhead lines or cables for mounting or stretching
Landscapes
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 특성 성분의 한약재로부터 추출된 플라보노이드와 타우린을 함께 포함하여, 간세포 보호 및 간기능 개선 등에 우수한 효과를 갖는 숙취해소제에 관한 것이다.The present invention includes a flavonoid and taurine, which are extracted from herbal medicines of specific ingredients, and relates to a hangover relieving agent having an excellent effect on liver cell protection and liver function improvement.
간은 인체에서 혈액 저장 및 순환, 혈액량 조절과 방어해독작용을 하며 정신적 활동과도 밀접하게 관련되어 있다고 알려져 있는 장기다. 우리 몸은 산업화에 따른 각종 공해물질, 유독 물질에 항상 노출되어 있으므로 간 또한 끊임없이 해독작용에 시달리고 있다. 더욱이 정신적인 스트레스로 인한 간 손상은 심각한 문제로써, 정신적 휴식을 가질 경우 손상된 간세포는 다시 복구되지만 바쁜 현대사회에서는 정신적 휴식을 취할 여유를 가질 수 없으므로, 정신적 스트레스, 과음, 흡연으로 간 손상을 더욱 가중시켜 인체가 방어 해독 작용을 하지 못함으로 인해 면역 체계에 이상을 가져와 다른 질병의 원인이 되기도 한다. 간은 완충능력이 큰 기관으로 질환의 초기단계에서는 잘 나타나지 않고 상당히 약화되어서야 발견된다.The liver is an organ that is known to be involved in blood storage and circulation, blood volume control and detoxification, and is also closely related to mental activity. Since our bodies are always exposed to various pollutants and toxic substances due to industrialization, the liver is also constantly suffering from detoxification. Furthermore, hepatic damage caused by mental stress is a serious problem. Damaged hepatocytes are restored when mental breaks occur, but in a busy modern society they cannot afford to take mental breaks. Because of the body's defense and detoxification effect due to the immune system may cause other diseases. The liver is a large buffering organ that does not appear well in the early stages of the disease and is found only when it is significantly weakened.
또한, 알코올은 그 높은 중독성과 치사율로 인해 전세계적으로 문제가 되고 있다. 알코올이 위나 장에서 흡수되어 대사가 이루어지는 곳은 간인데, 장기적이고 폭발적인 알코올의 섭취는 지방간, 알코올성 간염, 간경화를 유발한다. 자유라디칼 생성에 의한 산화적 손상이 알코올성 간질환을 유발하는 주요 기전이다. 에탄올의 첫 번째 대사산물은 알데히드다. 알데히드와 함께 생성되는 것이 높은 에너지를 지녀 매우 불안정한 반응성 산소군 (ROS) 인데 알데히드와 ROS는 순차적으로 대사되는 과정에서 세포막 지질의 과산화를 일으키고 DNA, protein 등 유전자 산물에 손상을 일으켜 간세포를 죽음으로 몰아넣는다. Alcohol is also a problem worldwide due to its high addictiveness and lethality. The alcohol is absorbed in the stomach or intestine where metabolism occurs. The long-term and explosive intake of alcohol causes fatty liver, alcoholic hepatitis, and cirrhosis. Oxidative damage caused by free radical production is a major mechanism causing alcoholic liver disease. The first metabolite of ethanol is aldehyde. Generated together with aldehydes is a highly unstable reactive oxygen group (ROS) that has high energy.Although aldehydes and ROS are sequentially metabolized, they cause peroxidation of cell membrane lipids and damage gene products such as DNA and proteins, leading liver cells to death. Put it in.
타우린은 황을 함유한 아미노산으로 간, 뇌, 심장, 근육 등 우리 몸의 각 부위에 분포하고 있으며 시스테인과 함께 산화적 손상을 막아주는 항산화제로 널리 알려져 있다. 또한 타우린은 세포 내 주요 양이온인 칼슘의 분포를 조절하여 세포를 급격한 사멸로부터 보호한다. 국내외적으로 타우린이 NO (nitric oxide), ROS (reactive oxygen species)의 생성을 막아 아세트아미노펜과 같이 산화적 손상을 유발하는 다양한 약물로부터 간을 보호한다는 연구가 꾸준히 진행되어 왔다Taurine is an amino acid containing sulfur, which is distributed in various parts of our body such as liver, brain, heart, and muscles, and is widely known as an antioxidant that prevents oxidative damage with cysteine. Taurine also regulates the distribution of calcium, a major cation in the cell, to protect the cell from sudden death. At home and abroad, research has been ongoing to protect the liver from various drugs that cause oxidative damage, such as acetaminophen, by preventing the production of nitric oxide (NO) and reactive oxygen species (ROS).
한편, 최근에는 이러한 간 독성의 예방 또는 치료를 위해 식용 및 약용 식물 등의 천연물을 통한 유리기(free radical) 생성 억제 작용에 대한 실험들이 많이 보고되고 있다(Caragy, A. B., Food Technology, 46, pp65-68, 1992; Liang jun, Y., et al., Biochem. and Biophy. Res. com., 212, pp360-366, 1995; Kim, H. K., et al., Korean J. Food Sci. Technol., 27, pp80-85, 1995; Middleton, E., Int. J. Pharmacognosy, 34, pp344-348, 1996). Recently, many experiments have been reported on the inhibition of free radical generation through natural products such as edible and medicinal plants for the prevention or treatment of liver toxicity (Caragy, AB, Food Technology, 46, pp65-). 68, 1992; Liang jun, Y., et al., Biochem. And Biophy.Res. Com., 212, pp360-366, 1995; Kim, HK, et al., Korean J. Food Sci.Technol., 27 , pp 80-85, 1995; Middleton, E., Int. J. Pharmacognosy, 34, pp 344-348, 1996).
그러나, 간 기능 개선 등에 있어서, 타우린 성분에 대한 구체적인 생리학적 기능 및 효능, 독성에 대한 자료가 없을 뿐만 아니라, 상기 타우린 성분과 함께 사용하여 상승효과를 얻을 수 있는 생약 추출물에 대한 연구 자체도 이뤄지지 않은 실정이다. 따라서, 타우린과 함께 천연물 유래의 간기능 개선용 식품 및 조성물 개발에 대한 연구가 필요하다.However, in the improvement of liver function, there is no data on specific physiological function, efficacy and toxicity of the taurine component, and there is no research on the herbal extract that can be synergistically used with the taurine component. It is true. Therefore, research on the development of foods and compositions for improving liver function derived from natural products with taurine is needed.
본 발명은 숙취해소와 알코올성 간질환의 예방과 치료에 큰 효과가 있는 플라보노이드(Flavonoid) 및 타우린을 포함하는 숙취해소제를 제공하고자 한다. The present invention is to provide a hangover relievers including flavonoids and taurine which has a great effect on the hangover and the prevention and treatment of alcoholic liver disease.
본 발명은 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초로 이루어진 군에서 선택된 1종 이상으로부터 추출된 플라보노이드, 및 타우린을 포함하는 숙취해소제를 제공한다. The present invention is a flavonoid extracted from one or more selected from the group consisting of baekchul, brown root, betel nut, hyangbuja, cinnamon, wagyang, sine, Yanggang, health, malt, singok, cloves, jinjin, dermis, red ginseng, essential, And it provides a hangover relievers comprising taurine.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 임상적으로 간 독성의 예방 또는 치료에 효과가 있을 것으로 예상되는 한방 복합제제의 간기능 개선 효능을 관찰함으로써 향후 간기능 개선 또는 간 독성 치료 약물로서의 개발 가능성을 평가하고자 하였다.The present invention was intended to evaluate the feasibility of improving liver function or developing hepatotoxicity drugs by observing the effect of improving the liver function of herbal combinations that are expected to be effective in preventing or treating liver toxicity.
특히, 한약재의 가장 기본적인 성분인 백출, 갈근, 맥아, 진피, 계피, 홍삼 등의 플라보노이드(Flavonoid)는 숙취 해소를 위한 음료의 보조적 성분으로 알코올 섭취로 인한 다양한 장기의 손상을 막아주고 알코올 대사 중간산물의 독성을 희석하는 데 우수한 효과가 있으며, 이들 플라보노이드(Flavonoid)는 주 약제인 타우린의 항산화 효과를 증진시키는 것이 밝혀졌다. In particular, flavonoids such as baekchul, brown root, malt, dermis, cinnamon, and red ginseng, which are the most basic ingredients of Chinese herbal medicine, are supplementary ingredients of beverages to relieve hangovers. It has been shown to be effective in diluting the toxicity of these flavonoids, and these flavonoids have been shown to enhance the antioxidant effect of the main agent taurine.
먼저, 본 명세서 전체에서, "숙취해소제"라 함은 명시적인 다른 기재가 없는 한, 한번에 복용 또는 투여되는 정제, 캡슐 또는 주사제와 같은 단일 단위 투여 형태뿐만 아니라, 2회 이상으로 나누어 투여되는 복수의 단위 투여 형태도 포괄하여 지칭할 수 있는 것으로 해석된다. 예를 들어, "플라보노이드 및 타우린을 포함하는 숙취해소제"라 함은 이들 2가지 활성 성분을 함께 포함하는 단일 단위 투여 형태뿐만 아니라, 각각이 하나씩의 활성 성분을 포함하는 두 개의 단위 투여 형태를 함께 지칭할 수도 있는 것으로 해석된다. 즉, 이들 두 개의 단위 투여 형태가 동시 또는 일정 시간 이하의 간격을 두고 투여되어, 이들 단위 투여 형태 각각에 포함된 2가지 활성 성분의 유효량이 체내에서 함께 존재해 상승 작용을 일으키는 경우, 위 두 개의 단위 투여 형태를 포괄하여 위 "플라보노이드 및 타우린을 포함하는 숙취해소제"의 범주에 속하는 것으로 지칭될 수 있다. First, throughout this specification, the term "hanging-up agent" means a single unit dosage form such as a tablet, capsule, or injection that is taken or administered at once, as well as a plurality of divided doses, unless stated otherwise. It is to be understood that the unit dosage form of can also be broadly referred to. For example, "hangover relievers comprising flavonoids and taurine" refers to a single unit dosage form comprising these two active ingredients together, as well as two unit dosage forms each containing one active ingredient. It is to be understood that it may refer to. That is, if these two unit dosage forms are administered simultaneously or at intervals of no more than a certain time, the effective amounts of the two active ingredients contained in each of these unit dosage forms are present in the body together and cause synergy. Including the unit dosage form may be referred to as belonging to the category of "hangover relievers comprising flavonoids and taurine".
또한, 본 명세서 전체에서 "플라보노이드"는 정제한 플라보노이드 및 그의 유도체, 이의 허용 가능한 염을 모두 포함하는 의미이다. 특히, 상기 플라보노이드는 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초로 이루어진 군에서 선택된 1종 이상의 한약재로부터 추출된 것이 될 수 있다. In addition, throughout this specification, "flavonoid" is meant to include all of the purified flavonoids and derivatives thereof, and acceptable salts thereof. In particular, the flavonoids are extracted from one or more medicinal herbs selected from the group consisting of baekryeok, brown root, betel nut, hyangbuja, cinnamon, wagyang, sine, Yanggang, health, malt, singok, cloves, injin, dermis, red ginseng, essential It can be done.
이때, 본 발명에서 추출 방법은 기존 천연물 추출에 사용 가능한 것으로 알려진 모든 추출법이 적용 가능하며, 예를 들면 열수 추출 후에 동결건조시켜 수분을 모두 제거하는 방법 등이 이용될 수 있다. At this time, the extraction method in the present invention is applicable to all extraction methods known to be available for extraction of existing natural products, for example, a method of removing all moisture by lyophilization after hot water extraction may be used.
바람직하게는, 상기 플라보노이드는 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초의 혼합물로부터 추출된 것이 될 수 있다. 좀더 바람직하게는, 상기 플라보노이드는 백출 추출물 10 내지 20 중량%, 갈근 추출물 5 내지 15 중량%, 빈랑 추출물 5 내지 15 중 량%, 향부자 추출물 5 내지 15 중량%, 계피 추출물 5 내지 15 중량%, 곽향 추출물 2 내지 7 중량%, 사인 추출물 2 내지 7 중량%, 양강 추출물 2 내지 7 중량%, 건강 추출물 2 내지 7 중량%, 맥아 추출물 2 내지 7 중량%, 신곡 추출물 2 내지 7 중량%, 정향 추출물 2 내지 7 중량%, 인진 추출물 2 내지 7 중량%, 진피 추출물 2 내지 7 중량%, 홍삼 추출물 2 내지 7 중량%, 필발 추출물 1 내지 3 중량%, 호초 추출물 1 내지 3 중량%, 및 잔량의 물을 포함하는 것이 될 수 있다. Preferably, the flavonoids may be extracted from a mixture of baekrye, brown root, betel nut, hyangbuja, cinnamon, wagyang, sine, Yanggang, health, malt, singok, cloves, jinjin, dermis, red ginseng, essential hair, and vinegar . More preferably, the flavonoids are 10 to 20% by weight of white extract, 5 to 15% by weight extract, brown extract 5 to 15% by weight, 5 to 15% by weight hyangbuja extract, 5 to 15% by
상기 플라보노이드에서 물의 함량은 전술한 바와 같이 동결건조시켜 수분을 모두 제거하는 경우에 전혀 포함되지 않을 수 있으며, 필요에 따라 0 내지 48 중량%로 포함될 수 있다. The content of water in the flavonoids may not be included at all in the case of removing all the moisture by lyophilization as described above, it may be included in 0 to 48% by weight as needed.
또한, 본 명세서 전체에서 "타우린"은 타우린(Taurine) 및 그의 유도체, 이의 허용 가능한 염을 모두 포함하는 의미이다. In addition, throughout this specification, "taurine" is meant to include both taurine (Taurine) and derivatives thereof, and acceptable salts thereof.
한편, 발명의 일 구현예에 따라, 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초로 이루어진 군에서 선택된 1종 이상으로부터 추출된 플라보노이드와 타우린을 함께 사용함으로써 보다 우수한 상승 효과를 나타내는 숙취해소제가 제공된다. 즉, 본 발명자들의 실험 결과, 놀랍게도 상기 한약재로부터 추출된 플라보노이드 및 타우린의 활성 성분을 조합 또는 배합하여 사용함에 따라, 이들 활성 성분의 조합이 특히 우수한 상승 작용을 일으켜 각각의 활성 성분의 사용시보다 동일 함량 또는 투여량 하에서 현저한 간기능 개선 효과를 나타낼 수 있음이 밝혀졌다. 특히, 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필 발, 및 호초로 이루어진 군에서 선택된 1종 이상으로부터 추출된 플라보노이드와 타우린을 조합 또는 배합하여 사용하면 보다 우수한 간기능 개선 효과를 나타낼 수 있음이 밝혀졌다. On the other hand, according to one embodiment of the invention, 1 selected from the group consisting of baekchul, brown root, betel nut, hyangbuja, cinnamon, wagyang, sine, Yanggang, health, malt, singok, cloves, jinjin, dermis, red ginseng, essential By using flavonoids extracted from species or more together with taurine, a hangover relieving agent having a better synergistic effect is provided. That is, as a result of the experiments of the inventors, surprisingly, as the active ingredients of flavonoids and taurine extracted from the herbal medicines are used in combination or in combination, the combination of these active ingredients produces a particularly excellent synergism, the same content than when using each active ingredient Or it has been found that can exhibit a significant improvement in liver function under the dose. In particular, flavonoids extracted from at least one member selected from the group consisting of baekchul, brown root, betel nut, hyangbuja, cinnamon, gwakyang, sine, Yanggang, health, malt, new song, cloves, injin, dermis, red ginseng, pistil, It has been found that the combination or combination of taurine may result in better liver function improvement.
따라서, 상기 발명의 일 구현예에 따른 숙취해소제는 상기 한약재로부터 추출된 플라보노이드의 유효량과 상기 타우린의 유효량을 포함할 수 있다. 보다 구체적으로, 상기 숙취해소제는 각 활성 성분을 이러한 함량으로 포함하여 1일 또는 1회에 투여 또는 복용되는 단일 투여 형태로 될 수 있다.Therefore, the hangover relieving agent according to the embodiment of the present invention may include an effective amount of the flavonoids extracted from the herbal medicine and the effective amount of the taurine. More specifically, the hangover releasing agent may be in a single dosage form containing or including each active ingredient in such a dose, which is administered or taken once or daily.
또한, 상기 발명의 일 구현예에 따른 숙취해소제는 각 제형의 형태에 따라 일반적으로 사용되는 충진제, 증량제, 결합제, 습윤제, 붕해제 또는 계면활성제 등의 희석제 또는 부형제를 더 포함할 수 있다. In addition, the hangover resolver according to an embodiment of the present invention may further include diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrating agents or surfactants generally used according to the form of each formulation.
그리고, 상기 발명의 일 구현예에 따른 숙취해소제는 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도에 따라 그 복용량 또는 복용 횟수가 당업자에게 자명하게 결정될 수 있다. 예를 들어, 플라보노이드의 유효량 및 타우린 유효량을 포함하는 상기 숙취해소제가 경구적 제형으로서 1일당 1회 내지 수회에 걸쳐 투여 또는 복용될 수 있다. 다만, 각 활성 성분의 복용량 또는 투여량이 각 활성 성분의 지나치게 높은 함량을 포함해 부작용을 초래하지 않을 정도로 되어야 함은 당업자에게 자명하다. And, hangover relieving agent according to an embodiment of the invention according to the weight, age, sex, health status, diet, administration time, administration method, excretion rate and the severity of the disease is obvious to those skilled in the art Can be determined. For example, the hangover relieving agent comprising an effective amount of flavonoids and an effective amount of taurine can be administered or taken as an oral formulation once to several times per day. However, it will be apparent to those skilled in the art that the dosage or dosage of each active ingredient should be such that it does not cause side effects, including an excessively high content of each active ingredient.
상술한 발명의 일 구현예에 따른 숙취해소제는, 이에 포함된 각 활성 성분의 우수한 상승 작용으로 인해, 각 활성 성분을 보다 감소된 함량으로 포함하면서도 동등하거나 더욱 우수한 간세포 보호 및 간기능 개선 효과를 나타낼 수 있다. 따라 서, 각각의 활성 성분의 높은 함량에 따른 부작용의 위험성을 크게 줄일 수 있으면서도, 우수한 간기능 개선 효과를 나타낼 수 있어 간기능 장애 관련 질병, 예를 들어, 지방간, 알코올성 간질환, 간경화, 또는 담즙울체 등의 치료 또는 예방에 매우 바람직하게 사용될 수 있다. Hangover relieving agent according to an embodiment of the present invention, due to the excellent synergistic action of each active ingredient contained therein, while containing each active ingredient in a reduced content while having the same or better liver cell protection and liver function improving effect Can be represented. Thus, while significantly reducing the risk of side effects due to the high content of each active ingredient, it can exhibit an excellent liver function improvement effect, such as diseases related to liver dysfunction, for example fatty liver, alcoholic liver disease, cirrhosis, or bile It can be very preferably used for the treatment or prevention of cryogens.
본 발명에 있어서 상기 기재된 내용 이외의 사항은 필요에 따라 가감이 가능한 것이므로, 본 발명에서는 특별히 한정하지 아니한다.In the present invention, matters other than those described above can be added or subtracted as required, and therefore, the present invention is not particularly limited thereto.
본 발명은 천연물로부터 유래된 한약재로서 백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초로 이루어진 군에서 선택된 1종 이상으로부터 추출된 플라보노이드와 타우린을 함께 사용함으로써, 간세포 보호 및 간기능 개선에 우수한 효과를 얻을 수 있다.The present invention is a herbal medicine derived from natural products, one selected from the group consisting of baekchul, brown root, betel nut, hyangbuja, cinnamon, gugyang, sine, Yanggang, health, malt, singok, cloves, jinjin, dermis, red ginseng, essential hair, By using the flavonoids extracted from the above and taurine together, excellent effects can be obtained in protecting liver cells and improving liver function.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the scope of the present invention is not limited to the following examples.
따라서 우리는 타우린의 알코올성 간독성 예방효과를 증명하고자 마우스 간세포인 TIB-73 cell을 가지고 알코올과 타우린을 함유한 플라보노이드(Flavonoid) 혼합물을 동시에 투여한 후 아래와 같은 방법으로 세포의 사멸 정도와 ROS의 생성여부를 실험하였다.Therefore, in order to prove the alcoholic hepatotoxicity of taurine, we simultaneously administered a mixture of alcohol and taurine-flavonoid containing flavonoids with TIB-73 cells, which are mouse hepatocytes. Was tested.
실시예Example 1 One
백출, 갈근, 빈랑, 향부자, 계피, 곽향, 사인, 양강, 건강, 맥아, 신곡, 정향, 인진, 진피, 홍삼, 필발, 및 호초의 한약재를 각각, 120 ℃에서 8시간 열수 추출한 후에 용기에 밀폐한 후 냉수 냉각하여 저온저장고에 보관하였다. Herbal extracts of baekchul, brown root, betel nut, hyangbuja, cinnamon, kwagyang, sine, Yanggang, health, malt, new song, cloves, jinjin, dermis, red ginseng, essential, and reef, respectively, are extracted in hot water at 120 ° C for 8 hours and sealed in a container. After cooling the cold water was stored in a cold storage.
각각의 한약재 추출물을 혼합하여, 백출 추출물 17.5 중량%, 갈근 추출물 8.8 중량%, 빈랑 추출물 8.8 중량%, 향부자 추출물 8.8 중량%, 계피 추출물 8.8 중량%, 곽향 추출물 4.4 중량%, 사인 추출물 4.4 중량%, 양강 추출물 4.4 중량%, 건강 추출물 4.4 중량%, 맥아 추출물 4.4 중량%, 신곡 추출물 4.4 중량%, 정향 추출물 4.4 중량%, 인진 추출물 4.4 중량%, 진피 추출물 4.4 중량%, 홍삼 추출물 3.7 중량%, 필발 추출물 2.2 중량%, 및 호초 추출물 1.7 중량%을 포함하는 플라보노이드를 제조하였다. Each of the herbal extracts were mixed, 17.5% by weight of white extract, 8.8% by weight of brown root extract, 8.8% by weight of betel extract, 8.8% by weight of hyangbuja extract, 8.8% by weight of cinnamon extract, 4.4% by weight of extract of sake extract, 4.4% by weight of sign extract, Yanggang Extract 4.4%, Health Extract 4.4%, Malt Extract 4.4%, Singok Extract 4.4%, Clove Extract 4.4%, Human Extract 4.4%, Dermis Extract 4.4%, Red Ginseng Extract 3.7%, Essential Extract Flavonoids were prepared comprising 2.2% by weight, and 1.7% by weight of a leaf extract.
상기 플라보노이드 50 ㎍/mL과 타우린 10 mM을 포함하는 숙취해소제[(F)+Tau]을 제조하였다.A hangover releasing agent [(F) + Tau] containing 50 μg / mL of the flavonoids and 10 mM of taurine was prepared.
비교예Comparative example 1 One
타우린을 함께 첨가하지 않고 플라보노이드 50 ㎍/mL 만을 포함하는 것을 제외하고는 상기 실시예 1과 동일한 방법으로 숙취해소제를 제조하였다.The hangover releasing agent was prepared in the same manner as in Example 1, except that only 50 μg / mL of the flavonoid was added without taurine.
비교예Comparative example 2 2
플라보노이드를 제조하지 않고 타우린 10 mM 만을 포함하는 것을 제외하고는 상기 실시예 1과 동일한 방법으로 숙취해소제를 제조하였다.A hangover releasing agent was prepared in the same manner as in Example 1, except that only 10 mM of taurine was included without preparing a flavonoid.
실험예Experimental Example 1 One
본 발명의 숙취해소제의 알코올성 간독성 예방효과를 확인할 수 있도록, 마우스 간세포인 TIB-73 cell을 사용하여 알코올과 함께 상기 실시예 1 및 비교예 1~2의 조성물을 동시에 투여한 후 아래와 같은 방법으로 세포의 사멸 정도와 ROS의 생성여부를 측정하였다.In order to confirm the alcoholic hepatotoxicity prevention effect of the hangover releasing agent of the present invention, the composition of Example 1 and Comparative Examples 1 and 2 together with the alcohol using the mouse liver cells TIB-73 cells in the following manner The degree of cell death and ROS production were measured.
먼저, 실험에 이용할 세포를 6 well에 깔고 24시간 배양한 뒤 하기와 같이 대조군과 실험군으로 나누고, 상기 실시예 1의 조성물과 비교예 1~2의 조성물과 함께 에탄올을 투여하여, 알코올성 간독성 예방 효과에 대한 평가를 수행하였다. First, the cells to be used in the experiment was placed in 6 wells and incubated for 24 hours, and then divided into a control group and an experimental group as follows, by administering ethanol together with the composition of Example 1 and the compositions of Comparative Examples 1 and 2, alcoholic hepatotoxicity prevention effect The evaluation was performed.
(1) 대조군: 에탄올 미처리군(1) control group: ethanol untreated group
(2) 실험군: Ethanol 2% 처리군(2) Experimental group:
(3) 비교예 1: 플라보노이드(Flavonoid) 50 ug/ml + 에탄올 2% 처리군 (3) Comparative Example 1: Flavonoids 50 ug / ml + 2% ethanol treatment group
(4) 비교예 2: 타우린(Taurine) 10 mM + 에탄올 2% 처리군 (4) Comparative Example 2: Taurine 10 mM +
(5) 실시예 1: 플라보노이드 50 ug/ml + 타우린 10 mM + 에탄올 2% 처리군Example 1
상기 대조군과 실험군, 실시예 1 및 비교예 1~2의 조성물 실험군에 대하여, 하기와 같이 LDH 테스트, MTT 테스트, 및 ROS 테스트를 수행하였다. For the control group and the experimental group, the experimental group of Example 1 and Comparative Examples 1 and 2, LDH test, MTT test, and ROS test was performed as follows.
LDHLDH 테스트( Test( LactateLactate dehydrogenasedehydrogenase , , LDHLDH testtest ))
타우린(Taurine)에 의한 알코올성 간세포 사멸 억제 효과를 검증하기 위해 LDH test를 하였다. 약물을 처리한 상태로 24시간 배양한 뒤 스펙트로포토미터(spectrophotometer, SpectraMax fluorometer with SoftMax Programme Molecular Probes, USA)를 이용하여 490 nm 파장에서 LDH를 측정했다.LDH test was performed to verify the effects of taurine on alcoholic hepatocyte death. After 24 hours of incubation with drugs, LDH was measured at 490 nm using a spectrophotometer (SpectraMax fluorometer with SoftMax Program Molecular Probes, USA).
MTTMTT 테스트 Test
세포의 생존여부를 알아보기 위한 추가실험으로 미토콘드리아의 기능성 여부를 확인하는 MTT 테스트를 시행하였다. 상기한 바와 같은 방법으로 대조군, 실험군 등을 나누고 약물을 처리하였으며 흡광도는 570 nm의 파장에서 측정하였다.As an additional experiment to determine the survival of the cell was performed MTT test to confirm the functional status of the mitochondria. In the same manner as described above, the control group, the experimental group, and the like were divided into drugs and absorbance was measured at a wavelength of 570 nm.
ROSROS 테스트 Test
알코올로 인한 간손상의 주요 매개체인 ROS 중에서 가장 많은 양 (약 55%)을 차지하는 H2O2의 양을 측정하기 위하여 2',7'-디틀로로플루오로씬스 디아세테이트(2',7'-Dichlorofluoresecin diacetate, DCFH-DA)로 세포를 염색하였다. 실험군은 위와 동일하게 설정하였으며 시약으로 세포를 염색한 1시간 뒤에 스펙트로포토미터(spectrophotometer, SpectraMax fluorometer with SoftMax Programme Molecular Probes, USA)를 이용하여 488 nm, 515 nm 파장에서 플루오로씬스(fluorescence)를 측정했다.2 ', 7'-Ditlofluorofluoros diacetate (2', 7) to determine the amount of H 2 O 2 , the largest mediator of alcohol-induced liver damage (ROS), approximately 55%. Cells were stained with '-Dichlorofluoresecin diacetate, DCFH-DA). The experimental group was set as above, and fluorescence was measured at 488 nm and 515 nm wavelengths using a spectrophotometer (Spectraphotometer, SpectraMax fluorometer with SoftMax Program Molecular Probes, USA) 1 hour after staining the cells with reagents. did.
상기 대조군 및 실험군, 실시예 1, 및 비교예 1~2의 조성물 군에 대한 LDH 테스트, MTT 테스트, ROS 테스트 결과는 각각 하기 표 1에 나타낸 바와 같으며, 대조군에 대한 상대적인 백분율 값으로 나타내었다. 하기 표 1의 단위는 %이다. LDH test, MTT test, ROS test results for the control group and the experimental group, Example 1, and the composition group of Comparative Examples 1 and 2 are as shown in Table 1, respectively, and expressed as a relative percentage value relative to the control group. The unit of Table 1 below is%.
또한, 상기 상기 대조군 및 실험군, 실시예 1, 및 비교예 1~2의 조성물 군에 대한 세포 생존성을 관찰하기 위하여, 약물 투여 24시간 후 세포의 변화를 현미경으로 관찰하고 (x200) 세포 사진을 촬영하여 도 1에 나타내었으며, 상기 실험예 1에 따른 LDH 테스트, MTT 테스트, ROS 테스트 결과를 각각 도 2~4로 나타내었다. In addition, in order to observe the cell viability of the composition of the control group and the experimental group, Example 1, and Comparative Examples 1 and 2, the change of the cells 24 hours after drug administration under a microscope (x200) and the cell picture Photographs are shown in FIG. 1, and the LDH test, MTT test, and ROS test results according to Experimental Example 1 are shown in FIGS. 2 to 4, respectively.
도 1에 나타낸 바와 같이, 2% 알코올을 투여한 실험군의 간세포는 본래의 모습을 잃고 죽어가고 있거나 이미 많은 세포가 죽어 세포의 밀도가 전체적으로 낮아졌으며 타우린 10 mM과 알코올을 같이 투여한 비교예 2의 경우에도 이러한 세포사멸이 일정부분 억제되었다. 그러나, 본 발명의 실시예 1에 따라 플라보노이드(Flavonoid)와 타우린을 병용 투여한 경우 가장 큰 알코올 독성 억제효과가 나타남을 알 수 있다.As shown in Fig. 1, the hepatocytes of the experimental group administered with 2% alcohol lost their original appearance or were already dying or had already lost many cells, resulting in a total decrease in cell density. In some cases, such apoptosis was suppressed. However, according to Example 1 of the present invention, when the flavonoid and taurine are administered in combination, it can be seen that the largest alcohol toxicity inhibitory effect is exhibited.
이는 상기 표 1및 도 2~3에 나타낸 바와 같이, 세포의 사멸 정도를 반영하는 두 가지 테스트인 LDH테스트와 MTT 테스트를 통해서도 확인할 수 있다. 특히, 알코올을 투여한 실험군의 세포는 사멸지표인 LDH가 급상승(80%)하였으며 생존지표인 MTT는 급하강(62%)하였다. 그러나, 본 발명에 따라 타우린과 플라보노이드의 혼합제제는 이러한 알코올에 의한 LDH 상승과 MTT 하강을 강력하게 억제하는 효과를 나타냈다.This can be confirmed through the two tests, LDH test and MTT test reflecting the degree of cell death, as shown in Table 1 and Figures 2-3. In particular, the cells of the experimental group to which alcohol was administered increased rapidly (80%) in LDH, which is an indicator of death, and dropped rapidly (62%), in MTT, which was a survival indicator. However, according to the present invention, the mixed preparation of taurine and flavonoids showed an effect of strongly inhibiting the LDH rise and the MTT drop caused by the alcohol.
이러한 테스트 결과로부터, 본 발명에 따라 타우린과 플라보노이드(Flavonoid)를 함께 포함하는 혼합제제가 알코올로 인한 간세포 사멸의 억제에 현저히 우수한 효과가 있음을 알 수 있다.From these test results, it can be seen that according to the present invention, a mixed preparation containing taurine and flavonoids together has a remarkably excellent effect on suppressing hepatocyte death due to alcohol.
또한, 상기 표 1 및 도 4에 나타낸 바와 같이, 알코올성 간손상의 주요 매개체인 ROS는 산화적인 손상을 가늠하는 지표에 있어서도, 알코올을 단독 투여한 실험군의 경우 큰 ROS의 상승 (50%)을 보였다. 그러나, 본 발명에 따라 타우린과 플라보노이드(Flavonoid)의 혼합제제와 알코올을 같이 투여하였을 때 이러한 ROS의 상승은 상당 부분 억제되었음을 알 수 있다.In addition, as shown in Table 1 and FIG. 4, ROS, which is a major mediator of alcoholic liver injury, showed a large increase in ROS (50%) in the experimental group administered with alcohol alone even in an indicator of oxidative damage. . However, it can be seen that the elevation of ROS is largely suppressed when the taurine and flavonoids are mixed with alcohol according to the present invention.
이상과 같이, 본 발명의 플라보노이드 및 타우린을 포함하는 숙취해소제를 사용함으로써, 마우스 간세포를 이용한 타우린의 알코올성 간세포 사멸 억제 실험에서 ROS의 생성을 효과적으로 억제하여 알코올로 인한 간세포의 사멸을 막아준다는 것이 밝혀졌다. 따라서, 이 실험 결과를 바탕으로 알코올로 인한 숙취의 해소와 알코올성 간질환의 치료에 있어, 본 발명에 따른 타우린과 플라보노이드의 혼합제제가 매우 우수한 효과를 나타낼 수 있음을 알 수 있다.As described above, by using the hangover releasing agent comprising the flavonoids and taurine of the present invention, it was found that effectively inhibits the production of ROS in the alcoholic hepatocyte killing experiments of taurine using mouse hepatocytes to prevent the death of hepatocytes by alcohol. lost. Therefore, on the basis of the experimental results, it can be seen that in the treatment of alcoholic hangover and the treatment of alcoholic liver disease, the mixed preparation of taurine and flavonoids according to the present invention can exhibit a very excellent effect.
도 1은 본 발명의 실험예 1에 따른 약물 투여 24시간 후 세포의 변화를 현미경으로 관찰하고(x200) 촬영한 세포 사진을 나타낸 것이다. Figure 1 shows the cell picture taken after observing the change of the cells 24 hours after the drug administration according to Experimental Example 1 of the present invention under a microscope (x200).
도 2는 본 발명의 실험예 1에 따른 LDH 테스트 결과를 그래프로 나타낸 것이다. 2 is a graph showing the LDH test results according to Experimental Example 1 of the present invention.
도 3는 본 발명의 실험예 1에 따른 MTT 테스트 결과를 그래프로 나타낸 것이다. 3 is a graph showing the MTT test results according to Experimental Example 1 of the present invention.
도 4는 본 발명의 실험예 1에 따른 ROS 테스트 결과를 그래프로 나타낸 것이다.4 is a graph showing the results of the ROS test according to Experimental Example 1 of the present invention.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090006833A KR20100087825A (en) | 2009-01-29 | 2009-01-29 | Hangover curing agent containing taurine and flavonoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090006833A KR20100087825A (en) | 2009-01-29 | 2009-01-29 | Hangover curing agent containing taurine and flavonoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100087825A true KR20100087825A (en) | 2010-08-06 |
Family
ID=42754188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090006833A KR20100087825A (en) | 2009-01-29 | 2009-01-29 | Hangover curing agent containing taurine and flavonoid |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20100087825A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101539864B1 (en) * | 2013-01-30 | 2015-07-28 | 이항종 | Beverage for curing of hangover |
| WO2016190546A1 (en) * | 2015-05-22 | 2016-12-01 | 성균관대학교 산학협력단 | Composition for preventing or treating liver disease comprising pogostemonis herba extract |
| CN107569637A (en) * | 2017-09-01 | 2018-01-12 | 赣州市青衫堂中草药有限公司 | Chinese medicine composition for treating hepatic sclerosis and preparation method and application |
-
2009
- 2009-01-29 KR KR1020090006833A patent/KR20100087825A/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101539864B1 (en) * | 2013-01-30 | 2015-07-28 | 이항종 | Beverage for curing of hangover |
| WO2016190546A1 (en) * | 2015-05-22 | 2016-12-01 | 성균관대학교 산학협력단 | Composition for preventing or treating liver disease comprising pogostemonis herba extract |
| CN107569637A (en) * | 2017-09-01 | 2018-01-12 | 赣州市青衫堂中草药有限公司 | Chinese medicine composition for treating hepatic sclerosis and preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101074158B1 (en) | Composition comprising polysaccharide extracted from panax ginseng preventing and treating liver diseases | |
| Birdane et al. | Anti-inflammatory and antinociceptive effects of Melissa officinalis L. in rodents | |
| US9011938B2 (en) | Methods and formulations for treating chronic liver disease | |
| KR101360231B1 (en) | Pharmaceutical composition for preventing or treating liver cancer comprising herbal extracts | |
| Xiao et al. | The effect of boletus polysaccharides on diabetic hepatopathy in rats | |
| AU2006209110B2 (en) | Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts | |
| WO2012050397A2 (en) | Pharmaceutical composition including herbal medicine extract for preventing or treating kidney cancer | |
| KR20100087825A (en) | Hangover curing agent containing taurine and flavonoid | |
| KR101360232B1 (en) | Pharmaceutical composition for preventing or treating renal cell carcinoma comprising herbal extracts | |
| CN104474135A (en) | Pharmaceutical composition with auxiliary protection function of treating chemical liver injury | |
| CN109925445A (en) | Anoectochilus causes the application in acute liver drug in preparation prevention and/or treatment D-Gal | |
| CN106620616A (en) | Pharmaceutical composition for preventing hair loss and promoting hair growth and preparation of pharmaceutical composition | |
| KR20200036715A (en) | Composition for improving fatigue recovery or exercise performance comprising angelica gigas nakai extract, cnidium officinale makino extract and paeonia japonica extract | |
| Ghanadi et al. | Phytotherapy: An anti-hepatotoxicity and hepatoprotective approach in chemotherapy | |
| Hebi et al. | Antidiabetic effect of aqueous Corrigiola telephiifolia in streptozotocin-induced diabetic rats | |
| KR20100133079A (en) | Herbal extracts composition for the prevention of alcoholic fatty liver, hyperlipidemia and hangover | |
| KR102167530B1 (en) | Composition comprising plant extract effective for skin health | |
| CN108379495B (en) | Application of galangal extract in preparation of preparation for preventing and/or treating non-alcoholic fatty liver disease | |
| Abascal et al. | The many faces of Silybum marianum (milk thistle): part 2-clinical uses, safety, and types of preparations | |
| KR101360233B1 (en) | Pharmaceutical composition for preventing or treating lung cancer comprising herbal extracts | |
| Yarnell et al. | Herbs for relieving chronic renal failure | |
| Alkushi | Protective effect of sorrel extract on adult rats treated by carbon tetrachloride | |
| Adam et al. | Hepatocurative effect of aqueous leaves extracts of Negro coffee (Cochlospermum tinctorium) on carbon tetrachloride induced liver injury in rats | |
| Hussein et al. | Ameliorating role of resveratrol on biochemical changes in experimentallyinduced liver fibrosis in rats | |
| KR20190118270A (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Withdrawal due to no request for examination |